Relay Therapeutics
Agent39 out of 100, Below median. Agent Readiness. Open the scores section.Agent Readiness: 39/100. Below median. Measured by StartupHub.ai. Median 41.Trust78 out of 100, Above median. Data Trust. Open the scores section.Data Trust: 78/100. Above median. Measured by StartupHub.ai. Median 61.Clinical-stage precision medicine company using protein motion insights for drug discovery.
About
Relay Therapeutics is a clinical-stage precision medicine company that integrates computational and experimental technologies to understand protein motion and transform drug discovery. Their proprietary Dynamo Platform visualizes how proteins move, enabling precise drug design for targets previously considered intractable. The company is advancing a pipeline of medicine candidates for precision oncology and genetic diseases.
Listed competitors
Also in this space
Biopharmaceutical company developing novel therapeutics for cancer and other diseases using chemoproteomics and covalent chemistry.
Shares Biotech, Drug Discovery
AI-driven drug discovery company developing novel medicines for unmet patient needs.
Shares Biotech, Drug Discovery
CBX Therapeutics is a biotechnology company focused on developing novel therapies for cancer.
Shares Biotech, Drug Discovery
Developing engineered biologics to harness the immune system for disease treatment.
Shares Biotech, Drug Discovery
Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.
Shares Biotech, Drug Discovery
Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.
Shares Biotech, Oncology
Key facts
- Website
- relaytx.com
- Headquarters
- Cambridge, United States
- Founded
- 2015
- Total funding
- $825M (Public Offering)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 20 May 2026 | Public Offering | $275M | |
| 8 Jan 2024 | Private Placement | $30M | |
| 20 Dec 2018 | Series C | $400M | |
| 14 Dec 2017 | Series B | $63M | |
| 14 Sept 2016 | Series A | $57M | Third Rock Ventures |
Tech stack
Detected on relaytx.com, last scanned 28 Oct 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- LinkedIn Insight Tag
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Proofpoint
- Cookie consent
- OneTrust
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is Relay Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Relay Therapeutics is 78 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Relay Therapeutics raised?
Relay Therapeutics has raised a total of $825M in funding. The most recent round on record is Public Offering.
SEC filings, insider activity, nonprofit links and pay benchmarks for Relay Therapeutics:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
